Accelerate diagnostics announces fda clearance of its accelerate arc™ system

An automated platform designed to fight against sepsis and antimicrobial resistance (amr) enables rapid, automated microbial identification on the bruker maldi biotyper® ca system directly from positive blood culture samples tucson, ariz. , sept. 30, 2024 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq: axdx), an innovator of rapid in vitro diagnostics, announced that the u.s. food and drug administration (fda) has granted 510(k) clearance of the accelerate arc system and bc kit, an innovative, automated positive blood culture sample preparation platform, for use with bruker's maldi biotyper® ca  system (mbt-ca system) and mbt-ca sepsityper® software extension.
AXDX Ratings Summary
AXDX Quant Ranking